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ABSTRACT
Ambulatory blood pressure (BP) correlates more
significantly with hypertension-associated
cardiovascular mortality and morbidity than
BP obtained in the doctor’s office. Assessing
ambulatory BP, either through 24-h monitoring
or through protocolized self-measurement at
home, is essential in diagnosing and
monitoring patients with hypertension.
Several ambulatory BP-derived indicators are
related with cardiovascular prognosis. These
include 24-h, daytime and nighttime BP
measurements, BP measurements obtained
through home self-measurement, dipping
status, morning surge, and BP variability. The
objective of this article was to review the effect
of olmesartan-based antihypertensive therapy
on the main risk variables obtained when
assessing ambulatory BP.
Keywords: Ambulatory blood pressure
monitoring; Ambulatory blood pressure; Blood
pressure; Home blood pressure monitoring;
Hypertension; Olmesartan
INTRODUCTION
Hypertension (HTN) is a key factor in the
development of cardiovascular disease. The
increase in blood pressure (BP) from optimal
levels correlates with coronary heart disease,
stroke, heart failure, sudden death, chronic
kidney disease, and peripheral arterial disease,
which are the leading causes of disease and
death in the world. HTN affects 30–40% of the
adult population. In addition, BP increases with
age so that the prevalence of HTN in the elderly
is over 50% [1–3]. In Spain, 33% of adults are
hypertensive and the prevalence of HTN in the
population over 60 years of age is close to 70%
[4]. Antihypertensive treatment is considered to
be one of the main achievements in medicine in
recent decades, since reducing high BP
significantly reduces HTN-related morbidity
and mortality [5].
Most of the basic concepts regarding HTN are
based on the classical measurement of BP in the
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doctor’s office. However, the main limitation of
this method is that it only offers a momentary
BP value that, in addition, is subject to factors
that may occasionally change it [6–8]. To
optimize assessing true BP values, techniques
have been developed to self-measure BP at
home, also called home BP monitoring
(HBPM) and automated BP measurement over
24 h or ambulatory BP monitoring (ABPM). The
BP levels obtained using HBPM [9–14] and those
recorded using ABPM [11, 15–21] are more
closely correlated with target organ damage
and cardiovascular disease than the BP levels
obtained in the doctor’s office. Ambulatory BP
measurement is currently considered a basic
indication for diagnosing and monitoring
patients with HTN [1, 22].
The objective of this article was to review the
studies on the effect of olmesartan-based
antihypertensive therapies on the main
prognostic indicators related to ambulatory BP.
METHODS
Olmesartan was chosen to perform this review
because recent studies analyzing the above-
mentioned variables have been developed
using this drug. A PubMed search was
conducted combining the terms ‘olmesartan’,
‘olmesartan and hydrochlorothiazide’,
‘olmesartan and amlodipine’, ‘olmesartan and
hydrochlorothiazide and amlodipine’, ‘home
blood pressure measurement’, and ‘ambulatory
blood pressure monitoring’. Furthermore,
additional searches were conducted using the
terms pertaining to treatments, and ‘blood
pressure control’, ‘ambulatory blood pressure
control’, ‘morning surge’, ‘blood pressure
variability’, and ‘chronotherapy’, selecting the
studies according to the review objective.
This article is based on previously conducted
studies and does not involve any new studies of





As mentioned previously, measuring
ambulatory BP is currently considered a basic
examination in diagnosing HTN and in
assessing the degree of BP control. The
recommendations from the British National
Institute for Health and Clinical Excellence
guidelines establish that either ABPM or HBPM
be performed to confirm the HTN diagnosis
[22]. The current guidelines from the European
Societies of Hypertension and Cardiology define
HTN both with the classic in-office figures as
well as with ambulatory BP levels [1]. Moreover,
ambulatory BP measurement improves the
assessment of patients with HTN by
determining a series of additional indicators.
The current ABPM and HBPM indications from
the European Societies of Hypertension and
Cardiology are listed in Table 1.
AMBULATORY BP CONTROL
MEASURED WITH ABPM
The assessment of ambulatory BP over a 24-h
period and the corresponding daytime and
nighttime periods is probably the main input
for ABPM. As for treated patients, ABPM enables
discerning between proper HTN control over
24 h and a lack of true control, not just while at
the doctor’s office. It is a well-known fact that
most patients with HTN need combined
treatment with two or more antihypertensive
drugs to achieve adequate control, and that
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probably 15–20% of patients need at least three
antihypertensive drugs [1]. In the analyses of a
national ABPM registry (Spanish ABPM
Registry), it has been observed that using a
combined antihypertensive treatment is
common, especially in cases with high
cardiovascular risk, but the ambulatory BP
control rate does not reach 50% [23–25]. The
data corresponding to the different
hypertensive subgroups are presented in
Table 2. In low-to-moderate-risk patients
without diabetes or kidney disease, a relatively
low use of combined treatments was observed,
being control rates less than 50%. This figure
was probably an expression of therapeutic
inertia or nihilism. In higher-risk patients,
with diabetes or kidney disease, the
therapeutic effort was higher but the control
rates were even more unfavorable.
Using combined antihypertensive treatment
earlier and a more systematic indication for
triple therapy when control is not achieved
Table 1 Indications for measuring ambulatory blood pressure according to the current guidelines from the European
Societies of Hypertension and Cardiology
Indications for HBPM or ABPM
Suspicion of white-coat HTN
Grade I HTN in the ofﬁce
HTN in individuals without asymptomatic organ damage and at low total CV risk
Suspicion of masked HTN
High normal BP in the ofﬁce
Normal ofﬁce BP in individuals with asymptomatic organ damage
Normal ofﬁce BP in individuals with high total CV risk
Identiﬁcation of white-coat effect in patients with HTN
Considerable variability of in-ofﬁce BP during a single visit
Considerable variability of in-ofﬁce BP over different visits
Suspicion of autonomic, postural, postprandial, siesta- and drug-induced hypotension
HTN or suspected pre-eclampsia in pregnant women
Identiﬁcation of true and false resistant HTN
Speciﬁc indications for ABPM
Marked discordance between in-ofﬁce BP and home BP
Assessment of dipping status
Suspicion of nighttime HTN or absence of dipping, such as in patients with sleep apnea, chronic kidney disease, or
diabetes
Assessment of BP variability
ABPM Ambulatory blood pressure monitoring, BP blood pressure, CV cardiovascular, HBPM home blood pressure
monitoring, HTN hypertension
Information from Ref. [1]
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with two drugs might result in improvements in
control rates. The most appropriate triple
combination has been considered to be one
that includes a renin–angiotensin system
blocker, a calcium-channel blocker, and a
diuretic [1]. As for olmesartan-based
combinations, two studies have assessed the
degree of control reached in ambulatory BP. In a
sub-analysis of the TRINITY trial (Triple therapy
with olmesartan medoxomil, amlodipine, and
hydrochlorothiazide in hypertensive patients;
ClinicalTrials.gov number, NCT00649389) the
effect of triple combination therapy was
assessed, with doses up to 40 mg of
olmesartan, 10 mg of amlodipine, and 25 mg
of hydrochlorothiazide, using ABPM in 440
patients with HTN defined as moderate to
severe based on a systolic BP C160 mmHg or a
diastolic BP C100 mmHg. After a 12-week
treatment period, 86.5% of patients presented
a mean 24-h BP\130/80 mmHg, 79.8% a mean
daytime BP\135/85 mmHg, and also 79.8% a
mean nighttime BP\120/80 mmHg [26].
In another sub-analysis, in this case the BP-
CRUSH study (Blood pressure control in all
subgroups with hypertension; ClinicalTrials.gov
number, NCT00791258), with a similar design
to the previous one and including 243 patients,
the degree of ambulatory BP control obtained
with the full doses of olmesartan, amlodipine,
Table 2 Prevalence of uncontrolled ambulatory blood pressure in different hypertensive subgroups and usage rates of
combination antihypertensive therapies: Data from the Spanish ABPM Registry
Gorostidi et al. [23]: comparison between high-risk and low/moderate-risk subjects with HTN
High-risk Low/moderate-risk
N 6534 10,685
Combination of 2 drugs (%) 27.2 19.6
Combination of 3 or more drugs (%) 31.4 13.3
24-h BP C130/80 mmHg (%) 76.3 63.9
Gorostidi et al. [24]: comparison between hypertensive subjects with and without diabetes
With diabetes Without diabetes
N 12,600 55,445
Combination of 2 drugs 25.1 20.2
Combination of 3 or more drugs 33.8 17.0
24-h BP C130/80 mmHg 59.3 55.4
Gorostidi et al. [25]: comparison between hypertensive subjects with and without kidney disease
With kidney disease Without kidney disease
N 5693 8689
Combination of 2 drugs (%) 25.9 21.6
Combination of 3 or more drugs (%) 40.2 20.4
24-h BP C130/80 mmHg (%) 56.5 53.8
ABPM ambulatory blood pressure monitoring, BP blood pressure, HTN hypertension
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and hydrochlorothiazide was 90.5% for mean
24-h BP, 88.4% for daytime BP, and 78.9% for
mean nighttime BP, defined as a BP \120/
70 mmHg [27]. The characteristics and the basic
results of these studies are presented in Table 3.
Logically, in other trials with double
combinations of olmesartan and
hydrochlorothiazide and of olmesartan and
amlodipine, the ambulatory BP control rates
were lower although more favorable than those
observed in daily practice. In the REZALT study
(Efficacy and tolerability of olmesartan
medoxomil and azelnidipine combination
therapy compared with monotherapy with
each agent in Japanese patients with essential
hypertension; Japan Pharmaceutical
Information Center registration number,
JapicCTI-060286), the combination treatment
with olmesartan and azelnidipine resulted in a
greater decrease in ambulatory BP than with the
corresponding monotherapies [28, 29]. In the
AZTEC study (AZOR trial evaluating blood
pressure reductions and control), with 290
subjects with HTN, 70.9% reached a mean
24-h ambulatory BP \130/80 mmHg with the
combination of olmesartan 40 mg and
amlodipine 10 mg [30].
In the APEX study (Ambulatory BP
monitoring study to evaluate the safety and
efficacy of an olmesartan medoxomil- and
amlodipine-based treatment regimen in
patients with type 2 diabetes and
hypertension), 207 patients with type 2
diabetes and HTN received a treatment titrated
until reaching the full dose of olmesartan and
amlodipine, and 70% of patients reached a
mean 24-h daytime BP \130/80 mmHg [31].
The SEVICONTROL-1 (Daytime systolic
ambulatory blood pressure with a direct switch
between candesartan monotherapy and the
fixed-dose combination olmesartan/
amlodipine in patients with uncontrolled
essential hypertension; ClinicalTrials.gov
number, NCT01613209) and SEVICONTROL-2
(Efficacy and safety of a therapy change from
candesartan 32 mg to fixed combination of
olmesartan 40 mg/amlodipine 10 mg;
ClinicalTrials.gov number, NCT01611077)
Table 3 Degree of ambulatory blood pressure control assessed using ambulatory blood pressure monitoring, in studies with
olmesartan-based triple combination




440 Sub-analysis of the TRINITY study. Patients
with moderate or severe HTN (systolic BP
C160 mmHg or diastolic BP C100 mmHg)
treated with OLM/AML/HCT up to 40/10/
25 mg
12 weeks 24-h BP\130/80 mmHg, 86.5%; daytime





243 Sub-analysis of BP-CRUSH study. Uncontrolled
patients with treated with monotherapy OLM/
AML/HCT up to 40/10/25 mg
20 weeks 24-h BP\130/80 mmHg, 90.5%; daytime
BP\135/85 mmHg, 88.4%; nighttime BP
\120/70 mmHg, 78.9%
AML amlodipine, BP blood pressure, BP-CRUSH blood pressure control in all subgroups with hypertension, HCT
hydrochlorothiazide, HTN hypertension, OLM olmesartan, TRINITY triple therapy with olmesartan medoxomil,
amlodipine, and hydrochlorothiazide in hypertensive patients study
a Outcomes obtained with the complete doses
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studies, in which 78 and 77 patients,
respectively, who were uncontrolled with
32 mg of candesartan, substituted this
treatment with the combination of olmesartan
40 mg and amlodipine 10 mg, directly in the
SEVICONTROL-1 study and sequentially in the
SEVICONTROL-2 study. The daytime
ambulatory BP control rates (mean daytime BP
\135/85 mmHg) in 12 weeks of treatment were
77.6% and 78.4%, respectively [32, 33].
The fact that the study protocols include
strict guidelines on increasing the dose or
combining drugs if the clinical BP is not
controlled, compared with a possible inertia in
routine clinical practice, is one of the factors
usually invoked to explain the differences in
control rates obtained in clinical trials




As mentioned in the introduction, home BP
measurements are more useful than in-office
measurements for HTN diagnosis, for predicting
cardiovascular events and for assessing
treatment efficacy. One study, called HONEST
(Home blood pressure measurement with
olmesartan naive patients to establish standard
target blood pressure; Trial registration number,
UMIN000002567), with olmesartan-based
treatment, was specifically designed to assess
the relationships between HBPM with the
effects of the therapy. HONEST observed the
relationships between the home measurement,
clinic measurement, and the incidence of
cardiovascular events in 22,373 patients
receiving olmesartan-based antihypertensive
treatment. Most studies about the
relationships between home BP measurements
and cardiovascular prognosis are observations
based on initial measurements. The HONEST
study will provide data on the prognostic value
of home measurements taken during follow-up
[35]. In the first publication of results, regarding
the short-term efficacy of the olmesartan-based
treatment guidelines, it was reported that the
percentage of patients who achieved adequate
control of clinic systolic BP (systolic BP
\140 mmHg) and home systolic BP (systolic
BP \135 mmHg), simultaneously, increased




The relationship between absolute ambulatory
BP levels and cardiovascular morbidity and
mortality is well established. Of the different
periods typically analyzed (24 h, day and night),
nighttime BP is the variable that is best
correlated with the prognosis. In addition, the
relationship between daytime BP and nighttime
BP (circadian profile) also predicts HTN-related
asymptomatic target organ damage and
cardiovascular events [1, 8, 18, 19, 21, 37].
Changes in the normal circadian profile (non-
dipper pattern) are very common in
hypertensive patients, affecting approximately
50% of cases [38]. There is a close relationship
between the non-dipper profile and
cardiovascular risk such that in patients at
high risk in general or in patients with
diabetes and HTN, the prevalence of this
change can reach 60% [23, 24].
Chronotherapy in HTN, or administering the
hypertensive treatment at a certain time of day,
proposes that taking the medication at night
has an added beneficial effect on the normal
decrease in BP by exercising a favorable action
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on the circadian profile with outcomes that
even improve morbidity and mortality [39].
However, this therapeutic approach is under
debate, as the results of other studies do not
corroborate these findings [40]. Regarding
olmesartan-based studies, in some, nighttime
administration of the drug has been described
to result in an added beneficial effect [41, 42]
whereas others have not reproduced these
results [43, 44]. In the COMPATIBLE study
(Comparison of effects of angiotensin II
receptor blocker on morning home blood
pressure and cardiorenal protection between
morning administration and evening
administration in hypertensive patients; Trial
registration number, UMIN000003238), 218
patients were randomized to take olmesartan
in the morning or at night and the reductions
in clinic BP, morning home BP, urinary
excretion of albumin, and electrocardiographic
parameters of left ventricular hypertrophy were
similar in patients who received the treatment
in the morning or at night [43].
MORNING SURGE IN BP
The increase in BP that is observed when waking
and especially when starting daily activity is
considered a physiological process. However,
there is a controversy about whether or not an
excessive morning BP surge may cause a
negative prognosis [8]. In this sense, it has
been recognized that the antihypertensive
treatment that minimizes the morning BP
surge, without causing excessive reductions
over the rest of the day, has an added
beneficial effect.
One of the most studied related variables is
the trough-to-peak ratio, considering the peak
time as the 2 consecutive hours with the largest
reduction in BP in the period between 2 and 8 h
after taking the treatment and the trough time
23 and 24 h after taking the treatment,
considering ideal the best proximity to the
unit that reflects a homogeneous effect over
24 h. Two recent studies with olmesartan-based
treatment have measured this variable. Both in
the EXPO study [45, 46] and in Bilo et al. [47],
the treatment caused a lasting effect over the
24-h period, with a trough-to-peak ratio greater
than 0.6. In the Bilo et al. [47] study, which also
assesses this parameter with the olmesartan and
amlodipine combinations, a more favorable
trough-to-peak ratio was observed in patients
who received the combination. Use of long-
acting antihypertensive drugs should be of key
importance for adequate BP morning surge
control. As shown in a recent meta-analysis,
losartan was less effective than other
angiotensin receptor blockers for controlling
24-h BP [48].
BP VARIABILITY
Although the cardiovascular complications of
HTN are essentially related to the absolute BP
levels, increased BP variability may have an
added deleterious effect. Thus, relationships
between cardiovascular morbidity/mortality
and very-short-term variability (beat to beat),
short term (in a 24-h period), long term
(between days), and very long term (between
doctor’s visits) have been described [49, 50].
There is a close relationship between
elevated BP levels, a higher cardiovascular risk,
and an increased variability in BP assessed using
ABPM [23]. In most of the studies mentioned so
far that have assessed this indicator, a reduction
in BP variability related to the reduction in
absolute BP levels caused by the various
treatments was observed. Thus, certain results
are of additional interest. In a post hoc analysis
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of Japan combined treatment with olmesartan
and a calcium-channel blocker versus
olmesartan and diuretics randomized efficacy
study, in which the patients initially treated
with olmesartan were randomized to receive
additional treatment with azelnidipine or with
hydrochlorothiazide, the patients treated with
olmesartan and the calcium-channel blocker
presented a higher reduction in day-to-day
variability as assessed using HBPM compared
to that observed in patients who received
olmesartan and the diuretic, despite similar
reductions in the absolute home BP levels. In
addition, a possible relationship was observed
between the reduction in variability and an
improvement in a marker of asymptomatic
target organ damage, such as aortic rigidity,
assessed by measuring carotid–femoral pulse
wave velocity [51].
One of the physiopathological changes most
closely related to increased BP variability is
sympathetic hyperactivity. Accordingly, the
results of a sub-analysis of the previously
mentioned studies are also of interest. Based
on the HONEST data, a higher relative
reduction in heart rate was observed in HBPM
readings in patients with higher baseline
ambulatory systolic BP and heart rate. This
tendency was clear in the patient subgroup
with chronic kidney disease, in which
sympathetic hyperactivity is usually greater.
The authors of this study concluded that
treatment with olmesartan may have an added
beneficial effect on intrarenal circulation in
patients with chronic kidney disease and the
resulting sympathetic hyperactivity [52].
LIMITATIONS
Most of the studies on the effect of olmesartan
and olmesartan-based treatments on variables
related to ambulatory BP included in this review
are open-label, non-comparative studies. These
limitations are recognized in the original
publications. Furthermore, the inclusion
criteria of this review exclude trials designed
the same as those mentioned carried out with
other therapeutic alternatives. In this regard,
there are studies on the effect of ambulatory BP,
mostly with ABPM, with double and triple
combinations based on different renin–
angiotensin system blockers [53–55] with
results in line with those mentioned for
olmesartan.
CONCLUSIONS
Assessing ambulatory BP, both for diagnosing as
well as for monitoring patients with HTN, and
improving the degree of overall HTN control are
currently priorities in managing this disease.
The results from the studies that have evaluated
the effect of olmesartan-based treatments
indicate that these have positive effects on the
ambulatory BP prognostic indicators such as
24-h BP control, nighttime BP control, BP
measured using self-measurement at home,
morning surge, and BP variability measured
using ABPM or HBPM. It would be desirable to
observe whether these benefits translate to
reductions in morbidity and mortality in
patients with HTN.
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